Details
Category: Volume 08 Issue 01 January 2020
Hits: 1277

Title: Weekly versus Biweekly High Dose Rate Brachytherapy Schedules in Carcinoma Cervix Following Concomitant Chemoradiation with Cisplatin

Authors: Dr Avni Kachhwaha, Dr H. S. Kumar, Dr M. R. Baradia, Dr Neeti Sharma, Dr Shankar Lal Jakhar, Dr Kamlesh Kumar Harsh

 DOI: https://dx.doi.org/10.18535/jmscr/v8i1.02

Abstract

Objective: The main objective of brachytherapy in carcinoma cervix is to deliver a lethal dose to tumour cells without inducing unacceptable damage to the surrounding normal tissue. Because the absorbed dose falls off rapidly, higher doses can be delivered safely to the targeted tissue over a short time. The aim of this study is to compare disease response, acute and late treatment related toxicities between two HDR brachytherapy regimens.

Material and Methods: 50 biopsy proven and registered FIGO stage IB2-IIIB cases of carcinoma cervix treated with concurrent CT (Inj. cisplatin 40 mg/m2 weekly) + EBRT up to 50Gy are included and randomised into two arms. In Arm A (control), HDR of 7.5Gy x 3# (weekly) is delivered to patients. In Arm B (study), HDR of 5.5Gy x 5# (biweekly) is delivered to patients. Disease response is evaluated by WHO criteria at the end of treatment, then at 1, 3 and 6 months to complete their 1 year follow up. Treatment related toxicities are also evaluated by RTOG guidelines at 1, 3 and 6 months up to 1 year.

Results: At 1st month, 96% in Arm A and 92% in Arm B, at 3rd and 6th month 84% in Arm A and 76% in Arm B shows complete response. At 1 year DFS is 84% in Arm A and 68% in Arm B. In late toxicity, Grade III and IV vaginal fibrosis and rectal complications were seen in 16% and 4% respectively in both arms. Grade III and IV bladder complications were observed in 0% in Arm A and 8% in Arm B.

Conclusion: This study suggests that both HDR fractionation schedules proved safe and well tolerated by patients. So, any of the regimens can be used depending upon patient factors and work-load of the institute.

Keywords: Ca cervix, HDR brachytherapy, disease response, late treatment toxicity, disease free survival.

References

  1. Maheshwari A, et al. Gynecological cancers: A summary of published Indian data. South Asian J Cancer. 2016 Jul-Sep; 5(3): 112–120.
  2. GLOBOCON 2018. http://gco.iarc.fr/today/data/factsheets/populations/356india-fact-sheets.pdf
  3. Burden of HPV related cancers. Human Papillomavirus and Related Diseases Report India. http://www.hpvcentre.net.
  4. https://www.webmd.com.
  5. Jain A, Ganesh B, Bobdey SC et al. Sociodemographic and clinical profile of cervical cancer patients visiting in a TCH in India. Indian Journal of Medical and Paediatric Oncology 2017 jul – sep;38(3): 291 – 295.
  6. Nag S, et al. The American Brachytherapy Society recommendations for High-dose-rate brachytherapy for carcinoma of the cervix. Int. J. Radiation Oncology Biol. Phys. 2000;201–211.
  7. Viswanathan AN, Creutzberg CL, Craighead P, et al. International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 2012;82(1):250–255. Copyright © 2012 Elsevier.
  8. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles, https://www.americanbrachytherapy.org/ABS/document-server/?cfp=ABS/assets/file/public/guidelines/Guidelines_Carcinoma_Cervix_Part1.pdf
  9. Petereit DG, Sarkaria JN, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32:1301–1307.
  10. Saptarshi Ghosh, Pamidimukalabramhananda Rao High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible? Journal of Obstetrics and Gynecology of India 2015;66(Suppl 1):1-7.
  11. Montana GS, Martz KL, Hanks GE. Patterns and sites of failure in cervix cancer treated in the USA in 1978. Int J Radiat Oncol Biol Phys. 1991;20(1):87–93.
  12. Gao Y, Jin-lu M, et al. The evaluation of older patients with cervical cancer. Clinical Interventions in Aging 2013:8 783–788.
  13. Shah A, Jena NK, et al. Role of Histopathological Differentiation as a Prognostic Factor for Treatment Response in Locally Advanced Squamous Cell Carcinoma Cervix Patients. Indian J Med Paediatr Oncol 2018; 39:282-6.
  14. Bonala SR, Pranabandhu D, et al. A Comparative Analysis of Two Different Dose Fractionation Regimens of High Dose Rate Intracavitary Brachytherapy in Treatment of Carcinoma of Uterine Cervix: A Prospective Randomized Study. Journal of Clinical and Diagnostic Research. 2017 Apr, Vol-11(4): XC01-XC05.
  15. Tharavichitkul E, Klunkin P, et al. The Effects of Two HDR Brachytherapy Schedules in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiation: A Study from Chiang Mai, Thailand. J. Radiat. Res., 53, 281– 287 (2012).
  16. Gogia P, Dhull AK, Kaushal V. Weekly versus biweekly high-dose rate brachytherapy schedules in carcinoma cervix following concomitant chemoradiation with paclitaxel and carboplatin. Asian J Oncol 2017; 3:12-16.

Corresponding Author

Dr H S Kumar

Senior Professor, Radiation Oncology Department, ATRCTRI, S. P. Medical College, Bikaner